Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, Blueprint acquisition, strong ...

Sanofi rode the growing sales wave for blockbuster immunology drug Dupixent (dupilumab) in Q2 but reported ...

Drugmaker Sanofi said on Thursday it believes the impact from U.S. tariffs to be manageable as it raised its sales growth ...

Dupixent global net sales, recorded by Sanofi (NASDAQ:SNY), grew 22% to $4.34 billion, while EYLEA HD U.S. net sales jumped 29% to $393 million. However, combined EYLEA HD and EYLEA U.S. net sales ...

Regeneron (REGN) stock in focus as the company surpasses Street's Q2 projections with strong growth in high-dose Eylea, ...

Sanofi Q2 sales rose 10.1% at constant currency, led by Dupixent and ALTUVIIIO. EPS missed estimates; 2025 sales guidance was revised upward.

Sales of EYLEA HD rose to $393 million from $304 million a year earlier thanks to increased demand. EYLEA sales, meanwhile, declined to $754 million from $1.23 billion, which the company attributed to ...

Sanofi reports strong Q2 2025 growth with innovative launches like Dupixent and strategic acquisitions boosting sales.

Although Sanofi delivered an earnings miss which still had encouraging results, SNY stock tanked, offering a potential ...

For now, Sanofi’s U.S. inventory is insulating the company from a potential 15% tariff on drugs shipped from the EU.

Regeneron-partnered Dupixent, the crown jewel of Sanofi’s commercial portfolio, continued to impress with 21.1% sales growth ...